ZA201106200B - Specific diarylhydantoin and diaryl thiohydantoin compounds - Google Patents

Specific diarylhydantoin and diaryl thiohydantoin compounds

Info

Publication number
ZA201106200B
ZA201106200B ZA2011/06200A ZA201106200A ZA201106200B ZA 201106200 B ZA201106200 B ZA 201106200B ZA 2011/06200 A ZA2011/06200 A ZA 2011/06200A ZA 201106200 A ZA201106200 A ZA 201106200A ZA 201106200 B ZA201106200 B ZA 201106200B
Authority
ZA
South Africa
Prior art keywords
diarylhydantoin
specific
diaryl
thiohydantoin compounds
compounds
Prior art date
Application number
ZA2011/06200A
Inventor
Rajendra Parasmal Jain
Jacqueline A Gibbons
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42665887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201106200(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of ZA201106200B publication Critical patent/ZA201106200B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/06200A 2009-02-24 2011-08-23 Specific diarylhydantoin and diaryl thiohydantoin compounds ZA201106200B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15511909P 2009-02-24 2009-02-24
US15639809P 2009-02-27 2009-02-27
PCT/US2010/025283 WO2010099238A1 (en) 2009-02-24 2010-02-24 Specific diarylhydantoin and diarylthiohydantoin compounds

Publications (1)

Publication Number Publication Date
ZA201106200B true ZA201106200B (en) 2013-07-31

Family

ID=42665887

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2011/06200A ZA201106200B (en) 2009-02-24 2011-08-23 Specific diarylhydantoin and diaryl thiohydantoin compounds
ZA2013/03499A ZA201303499B (en) 2009-02-24 2013-05-14 Specific diarylhydantoin and diarylthiohydantion compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2013/03499A ZA201303499B (en) 2009-02-24 2013-05-14 Specific diarylhydantoin and diarylthiohydantion compounds

Country Status (16)

Country Link
US (2) US8524755B2 (en)
EP (1) EP2400847B1 (en)
JP (2) JP2012518661A (en)
KR (1) KR20110130439A (en)
CN (1) CN102421291A (en)
AU (1) AU2010218052A1 (en)
BR (1) BRPI1007990A2 (en)
CA (1) CA2753425A1 (en)
ES (1) ES2535466T3 (en)
IL (1) IL214800A0 (en)
MX (1) MX2011008858A (en)
NZ (1) NZ594741A (en)
RU (1) RU2548918C2 (en)
SG (2) SG173837A1 (en)
WO (1) WO2010099238A1 (en)
ZA (2) ZA201106200B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
SG10201408699TA (en) * 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
AU2016208310B2 (en) * 2010-02-16 2017-10-05 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2014271290C1 (en) * 2010-02-16 2016-10-27 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
DK3329775T3 (en) * 2010-02-24 2021-07-26 Medivation Prostate Therapeutics Llc Methods for synthesizing diarylthiohydantoin and diarylhydantoin compounds
US20140088178A1 (en) * 2011-03-14 2014-03-27 The University Of British Columbia Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
MX359664B (en) * 2011-07-29 2018-10-05 Univ Colorado Regents Treatment of breast cancer.
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives
WO2013067131A1 (en) * 2011-11-02 2013-05-10 Medivation Technologies, Inc. Treatment methods
EP2664325A1 (en) * 2012-05-16 2013-11-20 PregLem S.A. Methods for preventing or treating androgen mediated diseases
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN104803919A (en) * 2014-01-26 2015-07-29 上海医药工业研究院 Preparation method of enzalutamide intermediate F
CN104844520B (en) * 2014-02-13 2017-09-05 成都伊诺达博医药科技有限公司 A kind of method for synthesizing the miscellaneous Shandong amine of grace
CN104844521B (en) * 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 The synthetic method of the miscellaneous Shandong amine of antiprostate cancer grace
RU2557235C1 (en) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
EP3230471B1 (en) 2014-12-12 2019-08-28 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
TWI613194B (en) 2015-06-10 2018-02-01 台灣神隆股份有限公司 A novel process for preparing enzalutamide
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
WO2018007624A1 (en) * 2016-07-08 2018-01-11 Actavis Group Ptc Ehf Enzalutamide derivatives for the treatment of prostate and breast cancer
CN107954936B (en) * 2016-10-17 2021-03-19 海创药业股份有限公司 Method for preparing deuterated imidazoldione compound
CN107501237B (en) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 Synthetic method of Apalutamide
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
JP2022509917A (en) 2018-11-05 2022-01-25 ファイザー・インク Combinations for treating cancer
JP2023537595A (en) 2020-08-13 2023-09-04 ファイザー・インク combination therapy
PE20240248A1 (en) 2020-12-11 2024-02-19 Ildong Pharmaceutical Co Ltd NEW COMPOUNDS AS A DUAL INHIBITOR OF THE ANDROGEN RECEPTOR AND PHOSPHODIESTERASE
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
KR20240060809A (en) * 2021-09-08 2024-05-08 어치브 라이프 사이언시즈, 인크. Analytical Methods for Assessing Cytisine Purity
WO2024127140A1 (en) 2022-12-17 2024-06-20 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136332B1 (en) 1970-12-09 1976-10-07
FR2715402B1 (en) * 1994-01-05 1996-10-04 Roussel Uclaf New phenylimidazolines optionally substituted, their process and preparation intermediates, their use as medicaments and the pharmaceutical compositions containing them.
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
US7173044B2 (en) * 2004-02-19 2007-02-06 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
US20060030871A1 (en) 2004-08-05 2006-02-09 Matthew Hain Vascular tunneler
JP2008511114A (en) * 2004-08-26 2008-04-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Lamp with reflective coating
WO2006028226A1 (en) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
ATE387259T1 (en) * 2005-05-13 2008-03-15 Protectron Nanocomposites Pte IMPROVED COLLOIDAL GEL FOR PROTECTIVE TEXTILE, IMPROVED PROTECTIVE TEXTILE AND PRODUCTION METHOD THEREOF
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (en) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 Diarylhydantoin compounds
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
EP2400847A4 (en) 2012-08-08
JP2015028085A (en) 2015-02-12
SG173837A1 (en) 2011-09-29
MX2011008858A (en) 2012-01-27
US20130331421A1 (en) 2013-12-12
ZA201303499B (en) 2015-03-25
BRPI1007990A2 (en) 2015-09-01
AU2010218052A1 (en) 2011-09-08
RU2011139107A (en) 2013-04-10
NZ594741A (en) 2014-03-28
WO2010099238A1 (en) 2010-09-02
RU2548918C2 (en) 2015-04-20
CA2753425A1 (en) 2010-09-02
CN102421291A (en) 2012-04-18
JP2012518661A (en) 2012-08-16
EP2400847A1 (en) 2012-01-04
IL214800A0 (en) 2011-11-30
EP2400847B1 (en) 2014-12-17
US9023879B2 (en) 2015-05-05
SG10201402628VA (en) 2014-10-30
ES2535466T3 (en) 2015-05-11
US20120035231A1 (en) 2012-02-09
KR20110130439A (en) 2011-12-05
US8524755B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
ZA201106200B (en) Specific diarylhydantoin and diaryl thiohydantoin compounds
HRP20180718T1 (en) Oligopeptidic compounds and uses thereof
PT3222617T (en) Psma-targeting compounds and uses thereof
GB0810179D0 (en) Object location
IL213309A0 (en) Conversation rights management
EP2465072A4 (en) Content rights management
GB2463514B (en) Imidazolidine compounds and uses therefor
EP2501697A4 (en) Benzoimidazole compounds and uses thereof
IL219504A0 (en) Quinazoline compounds
GB0902173D0 (en) Compounds and their use
GB0909768D0 (en) Novel compounds and uses thereof
HK1145675A1 (en) Quinazoline compounds
GB0922510D0 (en) Compound and use
EP2470022A4 (en) Compounds and methods
TWI367210B (en) Estrogenic-active compounds and application thereof
GB0905525D0 (en) Compounds and uses
PL387177A1 (en) Enaminocarbonylic compounds and their application
GB0905231D0 (en) Compounds and their use
GB0802666D0 (en) Compounds and their use IV
GB0908087D0 (en) Novel compounds and uses thereof
GB0902013D0 (en) Novel compounds and their use
GB0922284D0 (en) Preventing carcinosis
GB201206482D0 (en) #magnotherapy
GB0904939D0 (en) Applicator
GB0905085D0 (en) Applicator